Novo Nordisk Inc. et al v. Rio Biopharmaceuticals, Inc. et al
Novo Nordisk Inc. and Novo Nordisk A/S |
Rio Biopharmaceuticals, Inc. and EMS S/A |
1:2022cv00294 |
March 4, 2022 |
US District Court for the District of Delaware |
Colm F Connolly |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. ยง 271 Patent Infringement |
None |
Docket Report
This docket was last retrieved on March 14, 2022. A more recent docket listing may be available from PACER.
Document Text |
---|
SO ORDERED, re #9 STIPULATION TO EXTEND TIME for Rio Biopharmaceuticals Inc. and EMS S/A to answer, move or otherwise respond to the Complaint to May 9, 2022, filed by Novo Nordisk A/S, Novo Nordisk Inc. Reset Answer Deadlines: Rio Biopharmaceuticals, Inc. answer due 5/9/2022. Ordered by Judge Colm F. Connolly on 3/14/2022. (kmd) |
Filing 9 STIPULATION TO EXTEND TIME for Rio Biopharmaceuticals Inc. and EMS S/A to answer, move or otherwise respond to the Complaint to May 9, 2022 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
Filing 8 WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For EMS S/A waiver sent on 3/8/2022, answer due 5/9/2022. (Egan, Brian) |
Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:22-cv-00294-CFC through 1:22-cv-00299-CFC (rjb) |
Filing 7 SUMMONS Returned Executed by Novo Nordisk Inc., Novo Nordisk A/S. Rio Biopharmaceuticals, Inc. served on 3/7/2022, answer due 3/28/2022. (Egan, Brian) |
Filing 6 Summons Issued as to EMS S/A on 3/4/2022; Rio Biopharmaceuticals, Inc. on 3/4/2022. (Attachments: #1 Summons Issued EMS S/A)(mal) |
Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo A/S for Novo Nordisk A/S; Corporate Parent Novo Nordisk US Holdings, Inc. for Novo Nordisk Inc. filed by Novo Nordisk A/S, Novo Nordisk Inc.. (mal) |
Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2 ;9,132,239 B2 ;9,457,154 B2 ;9,687,611 B2 ;10,335,462 B2. (mal) |
Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 01/24/2022. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: 06/05/2025. (mal) |
Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
Filing 1 COMPLAINT filed against EMS S/A and Rio Biopharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3817543.) - filed by Novo Nordisk Inc. and Novo Nordisk A/S. (Attachments: #1 Exhibit A-E, #2 Civil Cover Sheet)(mal) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.